Clinical trials for Gout

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Gout. For all clinical trials, go to clinical trials search

This list shows clinical trials for Gout

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Gout
Title Recruitment status Location
Febuxostat versus Allopurinol Streamlined Trial (FAST) Recruiting United Kingdom
Colchicine Or Naproxen Treatment for ACute gouT Recruiting United Kingdom
Colchicine Or Naproxen Treatment for ACute gouT Recruiting United Kingdom
Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study Recruiting United Kingdom
Combination study of allopurinol and lesinurad in patients with gout not responding to allopurinol alone Not Recruiting United Kingdom
A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy - H2251 Not Recruiting United Kingdom
A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy - H2251 Not Recruiting United Kingdom
A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab at the time of gout flare. - H2251E1 Not Recruiting United Kingdom
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients Not recruiting United Kingdom
A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab at the time of gout flare. - H2251E1 Not Recruiting United Kingdom

Page last reviewed:

Next review due: